Sign In
Buy ALT
$2.84
-0.140 (-4.70%)
At Close: Jul 31, 2026
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
07:00am, Monday, 27'th Apr 2026
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital
Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Moderate Buy” from Analysts
02:22am, Monday, 27'th Apr 2026
Altimmune, Inc. (NASDAQ: ALT - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat.com reports. Two investment anal
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
02:16pm, Thursday, 23'rd Apr 2026
ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
02:10pm, Thursday, 23'rd Apr 2026
Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.
Is Altimmune a Buy Before Phase III MASH Starts in 2026?
02:06pm, Thursday, 23'rd Apr 2026
ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
11:25pm, Wednesday, 22'nd Apr 2026
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann
Altimmune Announces Proposed Underwritten Public Offering of Securities
04:19pm, Wednesday, 22'nd Apr 2026
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann
ALT5 Sigma Corporation Announces Planned Rebrand to AI Financial Corporation (AiFi) and Nasdaq Ticker Change
08:00am, Wednesday, 22'nd Apr 2026
Rebrand aligns next phase of platform strategy across payments, tokenization, and AI- driven financial infrastructure LAS VEGAS, NV / ACCESS Newswire / April 22, 2026 / ALT5 Sigma Corporation (NASDAQ:
Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M
01:05am, Saturday, 18'th Apr 2026
Altimmune (NASDAQ: ALT) shareholders approved all proposals presented at the company's virtual annual meeting on April 16, 2026, including the election of nine directors and amendments that expand the
ALT5 Sigma Corporation Reports Full Year 2025 Financial Results
08:00am, Monday, 13'th Apr 2026
ALT5's core fintech platform continued to scale in 2025, supported by growth across payments, trading, and settlement processing of approximately $3.5 billion in transaction volume during the year ALT
Altimmune (NASDAQ:ALT) versus TNF Pharmaceuticals (NASDAQ:TNFA) Head-To-Head Comparison
01:35am, Sunday, 05'th Apr 2026
TNF Pharmaceuticals (NASDAQ: TNFA - Get Free Report) and Altimmune (NASDAQ: ALT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two busi
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
12:06pm, Thursday, 26'th Mar 2026
Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
10:43am, Thursday, 26'th Mar 2026
Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.
ALT Pemvidutide Explained: What Makes It Different in MASH
10:26am, Thursday, 26'th Mar 2026
Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.
Altimmune: The High Cost Of Going Solo (Rating Downgrade)
02:47pm, Thursday, 12'th Mar 2026
Altimmune, Inc. appears undervalued on risk-adjusted NPV but faces severe funding and competitive headwinds. Pemvidutide's Phase 3 MASH program is ambitious, requiring significant capital, and now inc
